Search Results
Dec 22, 2025, 02:20 ET L&D Tech Selected as a World-Class Product with Its Energy-Saving LED Display; Receives Prime Minister's Award and Announces Global Launch
recognition underscores not only the technological innovation behind L&D Tech's energy-saving LED display but also its practical impact and proven reliability across real industrial environments. The product's core lies in L&D Tech's proprietary 3D-structured LED PKG and Half-Dome lens–based directional
More news about: L&D Tech
Dec 21, 2025, 20:56 ET Segway recibe el premio HKQAA
materia de sostenibilidad, en particular los principios de diseño ecológico que ejemplifican los patinetes eléctricos compartidos Apex D110 y Max S90L. En los últimos años, la empresa ha ampliado continuamente su compromiso con la sostenibilidad mediante el lanzamiento de productos ecológicos, cadenas
More news about: Segway
Dec 21, 2025, 20:54 ET Segway erhält HKQAA Award und hebt Fortschritte bei Produktnachhaltigkeit und sauberer Energie hervor
von Segway im Bereich der Nachhaltigkeit, insbesondere die umweltfreundlichen Konstruktionsprinzipien, für die die E-Scooter Apex D110 und Max S90L stehen. In den letzten Jahren hat das Unternehmen sein nachhaltiges Engagement in den Bereichen umweltfreundliche Produkteinführung, verantwortungsvolle
More news about: Segway
Dec 21, 2025, 20:52 ET Segway a reçu un prix de la HKQAA, qui souligne les progrès réalisés en matière de durabilité des produits et de leadership dans le domaine des énergies propres
développement durable, en particulier les principes de conception écologique illustrés par les trottinettes électriques partagées Apex D110 et Max S90L. Ces dernières années, l'entreprise a continuellement renforcé son engagement en faveur du développement durable en lançant des produits écologiques,
More news about: Segway
Dec 21, 2025, 20:00 ET 復星國際榮獲TVB頒發最高級別的「ESG年度卓越大獎」
癌症患者。其中，自主研發的創新型抗PD-1單抗H藥漢斯狀，是全球首個獲批用於一線治療小細胞肺癌的抗PD-1單抗。截至目前，H藥已在中國、歐盟、英國、新加坡、印度等近40個國家和地區獲批上市。今年以來，復星在創新藥領域實現多點破局。HLX43是一款靶向PD-L1的抗體偶聯藥物（ADC），正在中、美、澳等國家開展非小細胞肺癌、胸腺癌等實體瘤的臨床研究。目前，全球範圍內尚無PD-L1 ADC獲批上市，HLX43有潛力成為高效、安全的「廣譜抗癌藥」。12月7日，國家醫保局、人力資源社會保障部發佈2025年國家醫保目錄，復星醫藥旗下多款已上市的產品獲納入，而備受關注的首版商保
More news about: 復星
Dec 21, 2025, 20:00 ET Fosun International Honored with TVB's Highest Accolade, "Outstanding ESG Award"
field of innovative drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning
More news about: Fosun
Dec 20, 2025, 15:10 ET La híbrida enchufable Geely Riddara RD6 se lanza oficialmente en Chile, lo que acelera su expansión en el mercado mundial
desplazamientos urbanos, mientras que la energía híbrida permite realizar viajes de larga distancia. El consumo de combustible es de 1,5 L/100 km (NEDC) y de 6,7 l/100 km en modo de agotamiento de carga, lo que reduce los costos operativos en usos de logística urbana, agricultura y construcción.Fiel
More news about: Geely Riddara
Dec 20, 2025, 12:00 ET TORRAS Teams up With Artist GAWX to Launch "Guardian of Your Creativity" Collection Worldwide
December release, TORRAS announces a limited early-bird offer:Shop at: https://bit.ly/3L14XJnTheme: Guardian of Your CreativityCollection: TORRAS × GAWX Limited EditionLaunch Date: December
More news about: TORRAS Global
Dec 19, 2025, 14:46 ET Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
2017 Aug 3;377(5):442-453. doi: 10.1056/NEJMoa1612567. Erratum in: N Engl J Med. 2017 Oct 26;377(17):1700. doi: 10.1056/NEJMx170015.4. Winstedt L, et al. Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic
More news about: Hansa Biopharma AB
Dec 19, 2025, 14:43 ET Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
2017 Aug 3;377(5):442-453. doi: 10.1056/NEJMoa1612567. Erratum in: N Engl J Med. 2017 Oct 26;377(17):1700. doi: 10.1056/NEJMx170015.4. Winstedt L, et al. Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic
More news about: Hansa Biopharma AB
Dec 19, 2025, 12:54 ET Emergency Physicians Share Holiday Safety Tips
"Give yourself and loved ones the gift of safety this holiday season," said ACEP President L. Anthony Cirillo, MD, FACEP. "Simple precautions can help to ensure that this special time of year is spent celebrating with friends and loved ones, rather
More news about: American College of Emergency Physicians
Dec 19, 2025, 11:56 ET HR Leaders Face New Era of Workplace Transformation as New 'HR Chief' Platform Launches by Bizclik Media in February 2026
TechnologyAnalysis of how automation, generative AI, predictive analytics and emerging workplace technologies are transforming HR operations—from hiring and L&D to performance, engagement and workforce planning.
More news about: BizClik Media
Dec 19, 2025, 08:53 ET Invesco QQQ Shareholders Vote to Approve Modernization
Not all products, materials or services available at all firms. Financial professionals, please contact your home offices.Not a Deposit l Not FDIC Insured l Not Guaranteed by the Bank | May Lose Value | Not Insured by any Federal Government AgencyNA4919833 12/25Contact:
More news about: Invesco Ltd.
Dec 19, 2025, 08:00 ET Heritage Financial Corporation Appoints Scott T. Allan to its Board of Directors
Bank. Both appointments will become effective January 1, 2026."We are pleased to welcome Scott to our board of directors in January," said Brian L. Vance, Board Chair. "Scott is an experienced business leader and board member with a diverse background spanning engineering, consulting, venture-backed
More news about: Heritage Financial Corporation
Dec 19, 2025, 07:55 ET Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
levels."We're excited that these data continue to demonstrate a manageable safety profile and strong efficacy including deep and durable responses in 2L+ r/r DLBCL patients treated with ZYNLONTA plus glofitamab," said Mohamed Zaki, MD, PhD, CMO of ADC Therapeutics. "We are well on the way to completing
More news about: Equity Insider
Dec 19, 2025, 07:45 ET BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
two transformative medicines for people living with rare diseases, which impacted the lives of more than 3,400 patients around the world," said Bradley L. Campbell, President and Chief Executive Officer of Amicus. "With BioMarin's unwavering commitment to patients, along with greater resources and scale,
More news about: BioMarin Pharmaceutical Inc.
Dec 19, 2025, 07:18 ET The Return of KUKAN: An Oscar-Winning Documentary Legend Released Worldwide
what makes China unconquerable.https://youtu.be/l1wuKBz-SSI?si=vd7xuCmANvcFtSj8
More news about: iChongqing
Dec 19, 2025, 07:02 ET Real Range auf Real Road: Farizon SV demonstriert Weltklasse-Performance und beweist Reichweite in der Praxis
Straßenverhältnissen übertraf die Energieeffizienz von zwei der getesteten Varianten ihre offiziellen WLTP-zertifizierten Werte, während eine dritte Variante – ein L1H1 – eine Reichweitenerfüllung von 92,5 % erreichte.
More news about: Farizon New Energy Commercial Vehicle Group
Dec 19, 2025, 06:40 ET Реальная дальность хода на реальной дороге: модель Farizon SV демонстрирует характеристики мирового класса на испытаниях дальности хода в реальных условиях
как третий вариант — L1H1 — достиг уровня соответствия 92,5 %.Модель L3H3 высшего уровня,
More news about: Farizon New Energy Commercial Vehicle Group
Dec 19, 2025, 06:32 ET Weekly Recap: 13 Consumer Press Releases You Need to See
Molly Sims' YSE Beauty Closes $15M Series A Growth Equity Investment From Silas Capital and L Catterton In 2025, YSE Beauty experienced 120% revenue growth and expects to deliver more than 80% growth in 2026. The brand is anticipating to
More news about: PR Newswire
Dec 19, 2025, 05:46 ET CEO da Qlik: empresas estão entregando menos do que poderiam em IA, com ilhas de valor em um mar de ruídos
produtividade real. Neste momento, é uma camada invisível. Ela molda resultados, mas é invisível para na demonstração de resultados (Lucros e Perdas - P&L), raramente baseada em dados completos e totalmente fora da governança."Uma pesquisa recente do Boston Consulting Group revelou que apenas cerca
More news about: Qlik
Dec 19, 2025, 05:09 ET Life Time Opens Adults-Only Club in Uptown Boca on December 19; First Florida Location to Offer Coveted Athletic Reformer Class, CTR
healthy, happy lives through its 185 athletic country clubs across the U.S. and Canada, the complimentary and comprehensive Life Time app featuring its L•AI•C™ AI-powered health companion, and more than 30 iconic athletic events. Serving people ages 90 days to 90+ years, the Life Time ecosystem uniquely delivers
More news about: Life Time, Inc.
Dec 19, 2025, 03:00 ET ESR auf der CES 2026: Next-Gen-Innovationen für Laden, Schutz und Produktivität im Alltag
CryoBoost® auf den Markt, mit deutlich verbesserter Leistung und Nutzererfahrung:l Optimierter Luftstrom mit bis zu 6 °C geringerer Gerätetemperatur.l Reduzierte Lüfterlautstärke von nur 25 dB.l Schlankeres Design mit nur 4 mm Lüfterdicke.In Kombination mit
More news about: ESR Media
Dec 19, 2025, 03:00 ET The CHMP adopted a positive opinion for Vueway® (gadopiclenol) for its use in pediatric patients under 2 years of age
Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol 2024; 59(2):124-130.Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity. J Magn Reson Imaging
More news about: Bracco Group
Dec 18, 2025, 21:59 ET Kanazawa University research: a new strategy for immune tolerance
efficiently induced the differentiation and expansion of Foxp3⁺ Tregs. These induced Tregs expressed high levels of suppressive molecules such as CTLA-4, PD-L1, and LAG-3, and potently inhibited the proliferation of other T cells in a dose-dependent manner, demonstrating robust suppressive function.
More news about: Kanazawa University